"We're not doing that primarily because we think that that means that we're going to need to change that vaccine," he said. "So if a variant comes along for which there is clinical evidence of escape, we're ready to respond very quickly," Dormitzer added. Dormitzer, chief scientific officer of viral vaccines at Pfizer Vaccines Research and Development, said the company has already made a DNA template for a prototype vaccine and plans to manufacture a batch of that prototype. The company is proposing to do a Phase I clinical trial of a booster shot of that prototype vaccine that it would test against a booster for the current vaccine. And those studies are much, much smaller than the giant efficacy studies," Dormitzer said.

Source: bd News24 February 18, 2021 16:41 UTC